SNWV · SANUWAVE Health, Inc.
Market Cap
$42.67M
Shares
8.60M
Volume · Oct 19
58.49K
Avg daily vol (3M)
83.9K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.83
Open$5.05
Day$4.78–5.05
52W close$4.00–35.34
Avg vol 30d58K
Short int246K · 2.9% float · 3.9d
Short vol22%
Last earningsAug 7, 2026
DataOct 2024–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Dec 22, 2026
Est · unconfirmed
· in 9 wks
filed Aug 6, 2026
call held Mar 27, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$44.02M
Trailing 12 months
Net income (TTM)
$15.26M
Trailing 12 months
Revenue growth YoY
-3.1%
Year over year
Operating margin
3.4%
Trailing 12 months
P / E (TTM)
5.4
Trailing earnings · reciprocal yield 18.5%
FCF yield
9.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$9.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-6.2%
Year over year · fewer shares
Price change (1Y)
-85.8%
Trailing year
Short interest
2.9%
Latest settlement · 3.9 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
+1%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−74%
trailing
YTD return
−84%
this year
Relative strength
−81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $15 — 200d above 50d
Institutional flow
Distributing
5 of 49 funds reported for Sep 30 · net -14.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.85% of float · ▲ +2.2% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 4-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+35%
Y/Y
Gross margin
77%
expanding
EPS growth
+106%
Y/Y
Free cash flow
$1.9M
Balance sheet
$9.9M
net debt
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 12, 2026
Revenue
· full year 2026
Maintained
$51M – $55M
Mar 26, 2026
$51M – $55M
changed to
May 12, 2026
$51M – $55M
prior FY $44.05M
midpoint +20.3% Y/Y
Prior guidance
period ended
· from the 8-K filed May 12, 2026
Revenue
· Q2 2026
$11.1M – $11.6M
Guided vs delivered
· last 5 settled
Revenue
Q2 2026
guided $11.1M – $11.6M
$9.74M
Miss −14.2%
Revenue
Q1 2026
guided $9.6M – $10.3M
$9.62M
In line
Full year revenue
full year 2025
guided $44M – $45M
$44.05M
In line
Revenue
Q3 2025
guided $12M – $12.7M
$11.27M
Miss −8.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $15 — 200d above 50d
Institutional flow
Distributing
5 of 49 funds reported for Sep 30 · net -14.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.85% of float · ▲ +2.2% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 4-yr range
Price context
position in its 52-week range
Range low $4
Now $5 · 3%
Range high $35
vs 200-day avg -67%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $1.2M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA 149K
+0K Change in fair value of derivative liabilities
+1.57M Stock-based compensation
-532K State & local sales tax
+0K Sale of excess inventory
= Adjusted EBITDA 1.19M
|
|||
| EBITDA non-GAAP | $149K | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net (Loss) Income -682K
+518K Interest expense
+313K Depreciation and amortization
= EBITDA 149K
|
|||
| Ultramist® applicator revenue | $7.3M | Q2 2026 | +12.1% |
|
|
|||
| Ultramist® systems sold | 82 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNWV
this stock
SANUWAVE Health, Inc.
|
$42.67M | -83.8% | +35.0% | — | 2.9% |
|
ABT
Abbott Laboratories
|
$180.99B | -16.9% | +5.7% | 33.6 | 0.8% |
|
MDT
Medtronic plc
|
$121.20B | -3.4% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$113.02B | -15.2% | +11.2% | 30.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.16B | -52.8% | +12.5% | 18.2 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNWV | -17.3% | +8.8% | -73.8% | +2.6% | -83.8% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -15.8% | +9.7% | -81.5% | +2.1% | -96.2% |